Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.
AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.
Introduction: The role of PD-1 signaling in regulatory T cells (Tregs) remains controversial. Previous studies have primarily studied the role of PD-1 signaling on Tregs indirectly through PD-1 knockout models or PD-1/PD-L1 blocking antibodies. DBP is a de novo miniprotein PD-1 agonist designed using a deep-learning framework. We hypothesized that PD-1 stimulation enhances Treg activation and suppressive function and aimed to study the effect of direct PD-1 stimulation on human Tregs in vitro using DBP.
Methods: Human CD25+ T cells, isolated from peripheral blood mononuclear cells (PBMCs) from healthy donors using magnetic-activated cell sorting (MACS), were cultured with plate-coated stimulating anti-CD3 antibodies (p-aCD3, 1.0µg/ml), soluble anti-CD28 antibodies (s-aCD28, 0.5µg/ml) and IL-2 (250IU/ml) with DBP at 200nM, 20nM or IgG1 isotype antibody control for up to 96 hours. Changes in CD25, Foxp3, Helios, T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) and Lymphocyte Activation Gene 3 (LAG3) expression were measured using flow cytometry and IL-10 concentrations in the supernatant were measured using ELISA. In vitro suppression assays were performed using expanded Tregs with or without DBP at 200nM and 20nM. The proliferation of VPD-stained flow-sorted Tregs and CSFE-stained CD25- T conventional cells (Tconvs) were measured after 90 hours of co-culture with and without DBP.
Results: DBP 200nM treatment increased the frequency of CD4+Foxp3+ cells amongst total lymphocytes (p=0.048, Fig 1a) and Foxp3+Helios+ cells amongst CD4+ cells (p=0.009, Fig 1b) at 96 hours. CD25, TIGIT and LAG3 expression did not differ between DBP and control (Fig 1c & 1d), and no differences in IL-10 concentrations were detected in the supernatant. Suppression of MACS-selected T cells or unsorted PBMCs by Tregs was not enhanced with DBP (Fig 2a-b). Co-cultures did not demonstrate differential growth between Tregs and Tconvs with and without DBP (Fig 2c).
Conclusions: PD-1 stimulation of Tregs using a stimulating de novo miniprotein in vitro increased Foxp3 and Helios expression but did not enhance Treg activation markers or suppressive function. Given the established impact of PD-1 signaling on Tconvs, a possible differential effect of DBP on Tregs vs. Tconvs could offer a promising therapeutic approach. Further investigations are planned to explore this potential.